ELTX — Elicio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1601485 ·
Last close
$10.03
Market Cap
$191.43M
52W High
$14.93
52W Low
$9.11
ADV30
138,964
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,602,000 | -11,823,000 | 22,689,000 | 14,948,000 | 24,126,000 |
| Dec 2025 | 0 | — | -8,842,000 | -7,718,000 | 25,862,000 | 18,563,000 | 24,226,000 |
| Sep 2025 | 0 | — | -8,045,000 | -10,083,000 | 28,284,000 | 20,611,000 | 24,468,000 |
| Jun 2025 | 0 | — | -9,676,000 | -10,561,000 | 29,528,000 | 22,088,000 | 27,694,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,952,000
Investing CF
$-16,000
Financing CF
$36,695,000
CapEx
$-45,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.52
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-233,672,000
Inventory
—
Receivables
$2,000
ST Investments
—
EBIT TTM
$-38,438,000
Pretax Income TTM
$-39,571,000
Interest Exp TTM
$1,133,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,299,000 | -39,571,000 | 25,862,000 | 24,226,000 | — | -36,952,000 |
| Dec 2024 | 0 | -44,986,000 | -51,898,000 | 28,178,000 | 39,490,000 | — | -37,068,000 |
| Dec 2023 | 0 | -35,745,000 | -35,195,000 | 27,146,000 | 15,773,000 | — | -32,694,000 |
| Dec 2022 | 0 | -23,733,000 | -28,208,000 | 22,664,000 | 124,809,000 | — | -22,179,000 |
TTM Snapshot
Revenues TTM
$6,683,000
NetIncome TTM
$-52,398,000
OpCashFlow TTM
$0
Assets (Latest)
$28,178,000
Forward EPS
$-1.76
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLSA | Tiziana Life Sciences Ltd | $192.16M | $1.51 | — |
| RNAC | Cartesian Therapeutics, Inc. | $189.51M | $6.45 | — |
| UNCY | Unicycive Therapeutics, Inc. | $188.50M | $7.06 | — |
| GALT | GALECTIN THERAPEUTICS INC | $183.74M | $2.79 | — |
| KPTI | Karyopharm Therapeutics Inc. | $203.29M | $8.97 | — |
News headlines (Yahoo Finance, 1h cache)
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-11 20:05 · Yahoo
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
2026-04-30 12:00 · Yahoo
Elicio Therapeutics Reports Inducement Grants
2026-04-16 12:00 · Yahoo
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
2026-03-20 13:40 · Yahoo
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
2026-03-18 13:55 · Yahoo
Elicio Therapeutics: Q4 Earnings Snapshot
2026-03-12 22:09 · Yahoo
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-12 20:05 · Yahoo
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-25 13:00 · Yahoo
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership
2026-01-28 11:55 · Yahoo
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
2025-12-11 17:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.